DiaMedica raises $11.8M in private placement at $2.50/share; funds stroke and preeclampsia trials

DiaMedica Therapeutics Inc.

Gross proceeds $11.8M from sale of 4.72M shares at $2.50/share; expected close June 28, 2024.
Net proceeds to fund DM199 phase 2/3 ReMEDy2 trial for acute ischemic stroke and expansion into preeclampsia.
Cash runway extended into Q3 2026.
Non-management related parties committed $6.0M (2.4M shares); exempt from MI 61-101 valuation and minority approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.